Evidence map›Paper›PMID 32635175›Full record

ArticleCancers2020

Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy.

Marika Porrazzo, Emanuele Nicolai, Mara Riminucci, Candida Vitale, Marta Coscia, Lorenzo De Paoli, Angela Rago, Giulia Buscicchio, Giacomo Maestrini, Silvio Ligia and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. A clinical-radiomic model based on best subset regression for prognostic prediction in natural killer/T-cell lymphoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Marika PorrazzoHematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161 Rome, Italy.
Emanuele NicolaiInstitute of Diagnostic and Nuclear Research, IRCCS SDN, 80143 Naples, Italy.
Mara RiminucciDepartment of Molecular Medicine, "Sapienza" University of Rome, 00161 Roma, Italy.ORCID 0000-0002-8643-9211
Candida VitaleDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Turin, 10124 Torino, Italy.ORCID 0000-0002-2592-8724
Marta CosciaDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Turin, 10124 Torino, Italy.ORCID 0000-0003-2123-7675
Lorenzo De PaoliDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy.
Angela RagoUOSD Hematology, ASL Roma 1, 00193 Rome, Italy.ORCID 0000-0002-2432-235X
Giulia BuscicchioDepartment of Psychology, Catholic University of the Sacred-Heart, 20123 Milan, Italy.ORCID 0000-0002-1390-3124
Giacomo MaestriniHematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161 Rome, Italy.
Silvio LigiaHematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161 Rome, Italy.
Alessio Di PrimaHematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161 Rome, Italy.
Alessandro CorsiDepartment of Molecular Medicine, "Sapienza" University of Rome, 00161 Roma, Italy.ORCID 0000-0001-6896-4509
Roberto CaronnaDepartment of Surgical Sciences, Sapienza University, 00161 Rome, Italy.ORCID 0000-0002-4683-2756
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy.
Francesca Romana MauroHematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161 Rome, Italy.
Sapienza University of Rome · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Turin · ITASL Roma · ITSDN Istituto di Ricerca Diagnostica e Nucleare · ITUniversità Cattolica del Sacro Cuore · IT

Funding

Associazione Italiana per la Ricerca sul Cancro AIRC 5 x 1000 No. 21198
6 · The paper itself

Abstract

The role of positron emission tomography/computed tomography (PET/CT) in identifying Richter Syndrome (RS) is well established, while its impact on the survival of patients with chronic lymphocytic leukemia (CLL) has been less explored. The clinical characteristics and PET/CT data of 40 patients with a biopsy-proven CLL who required frontline chemoimmunotherapy, FCR (fludarabine, cyclophosphamide, rituximab) in 20 patients, BR (bendamustine, rituximab) in 20, were retrospectively analyzed. Standardized uptake volume (SUV

Indexed as

chronic lymphocytic leukemiaPET/CTsurvival

Identifiers

PMID32635175
PMCPMC7408608
OpenAlexW3039158786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.